Skip to content

Study · Non-randomized trial · n = 100 · 1997

2 results

Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.

Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG

Acta orthopaedica Scandinavica. Supplementum1 Oct 1997Cited by 71 (Europe PMC)

PMID9385283 (opens in a new tab)DOI10.1080/17453674.1997.11744761 (opens in a new tab)PepBankPUB-09385283
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with vertebral fractures, calcitonin accompanied early mobilization and restored locomotor function, whereas placebo recipients remained in bed.

    In plain wordsIn patients with vertebral fractures, movement recovered during calcitonin treatment, while placebo recipients remained in bed.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseMobilization and locomotor function
    Study

    n = 100

    Comparator
    placebo nasal spray
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · 28 daysAs given in this study (human).

    Source sentences

    Summary
    This analgesic effect was accompanied by early mobilization and gradual restoration of the locomotor functions, such as sitting, standing and walking.
    3 context sentences
    Summary · context
    Patients receiving the placebo nasal spray remained in bed for almost the entire period of observation.
    Summary · context
    We examined the analgesic effect of nasal salmon calcitonin in patients with acute pain due to recent, nontraumatic osteoporotic vertebral crush fractures.
    Summary · context
    32 men and 68 postmenopausal women were studied using a prospective, double-blind, placebo-controlled clinical design.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with recent osteoporotic vertebral fractures, nasal calcitonin markedly decreased spinal pain.

    In plain wordsIn patients with recent osteoporotic vertebral fractures, spinal pain decreased during nasal calcitonin treatment.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSpinal pain
    Study

    n: not reported in source

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Men and women taking 200 IU of nasal salmon calcitonin daily for a period of 28 days had a dramatic decrease of spinal pain.
    2 context sentences
    Summary · context
    We examined the analgesic effect of nasal salmon calcitonin in patients with acute pain due to recent, nontraumatic osteoporotic vertebral crush fractures.
    Summary · context
    32 men and 68 postmenopausal women were studied using a prospective, double-blind, placebo-controlled clinical design.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.